Get the Stockscreener App
0.7201
3.02%
0.0211
Cyclo Therapeutics Inc stock is traded at $0.7201, with a volume of 17,885.
It is up +3.02% in the last 24 hours and down -6.96% over the past month.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
See More
Previous Close:
$0.699
Open:
$0.7031
24h Volume:
17,885
Relative Volume:
0.38
Market Cap:
$20.23M
Revenue:
$1.13M
Net Income/Loss:
$-20.74M
P/E Ratio:
-0.383
EPS:
-1.88
Net Cash Flow:
$-18.37M
1W Performance:
+1.42%
1M Performance:
-6.96%
6M Performance:
-48.56%
1Y Performance:
-48.56%
1-Day Range:
$0.6501
$0.729
1-Week Range:
$0.6147
$0.74
52-Week Range:
$0.5946
$2.115
Cyclo Therapeutics Inc Stock (CYTH) Company Profile
Name
Cyclo Therapeutics Inc
Sector
Phone
386-418-8060
Address
6714 NW 16TH STREET, SUITE B, GAINESVILLE
Compare CYTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CYTH | 0.7201 | 20.23M | 1.13M | -20.74M | -18.37M | -1.88 |
| ZTS | 176.34 | 79.52B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.54 | 43.13B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.4259 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.46 | 18.56B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.02 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Cyclo Therapeutics Inc Stock (CYTH) Latest News
TeleChoice International’s Path to Exiting SGX Watch-list - MSN
Cyclo Therapeutics Inc (CYTH) Quarterly 10-Q Report - Quartzy
Cyclo Therapeutics Completes Phase 3 Trial Enrollment, Plans 2025 NDA Filing Amid Merger | CYTH Stock News - StockTitan
Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Well Health Stock: Buy, Sell, or Hold? - MSN
Canopy Growth (CGC) Stock Dives Amid Financial Struggles and Ind - GuruFocus.com
AMGN Stock Drops 5% Amid Industry Decline and Earnings Report - GuruFocus.com
Siga Technologies (SIGA) Sees Significant Stock Decline Amidst P - GuruFocus.com
Niemann-Pick Disease Type C Pipeline 2024: Clinical Trials - openPR
Astrazeneca: How a fraud investigation crashed a FTSE 100 giant - MSN
Rafael Holdings Inc. Class B (RFL) Annual 10-K Report - Quartzy
Analysts Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) PT at $8.00 - Defense World
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - ForexTV.com
Rafael Holdings Reports $34.4M Loss, Inks Merger Deal with Cyclo Therapeutics | RFL Stock News - StockTitan
Sofi Technologies Inc (SOFI-Q) QuotePress Release - The Globe and Mail
Pacira BioSciences Reports Third Quarter 2024 Financial Results - The Manila Times
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
Pilgrim's Pride (PPC-Q) QuotePress Release - The Globe and Mail
Kuehn Law Encourages CDE, SMC, COFS, and RFL Investors to Contac - GuruFocus.com
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals - BioCentury
Sonoma Pharmaceuticals (SNOA) Surges Amid Positive Analyst Ratin - GuruFocus.com
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
What Q3 investment banking trends reveal about the economy - Fortune
Will Cyclo Therapeutics Get A Boost From NPC-1 Trial Data? - RTTNews
Pacira BioSciences Appoints Shawn Cross As Chief Financial Officer - citybiz
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer - The Manila Times
Niemann Pick Disease Drug Type C Treatment Market Industry - openPR
Deal Watch: Lilly Turns To Oblique For Antibody Discovery - Scrip
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
Alkermes (ALKS) Stock Surges Amid Strong Financial Results - GuruFocus.com
Maxim Group Downgrades Cyclo Therapeutics (CYTH) - MSN
Cyclo Therapeutics faces Nasdaq delisting over non-compliance - Investing.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Increased by Handelsbanken Fonder AB - Defense World
Cyclo Therapeutics faces Nasdaq delisting over non-compliance By Investing.com - Investing.com UK
Cyclo Therapeutics secures $3 million in funding from Rafael Holdings By Investing.com - Investing.com South Africa
Cyclo Therapeutics secures $3 million in funding from Rafael Holdings - Investing.com India
Kuehn Law Encourages CDE, SMC, COFS, and RFL Investors to Contact Law Firm - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, SMC, COFS, RFL on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX - AccessWire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FYBR, COFS, RFL on Behalf of Shareholders - Lelezard.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders - AccessWire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, MNTX, RFL on Behalf of Shareholders - The Malaysian Reserve
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law Firm - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, GATO, RFL on Behalf of Shareholders - The Malaysian Reserve
Take your (Niemann-) Pick: Intrabio’s Aqneursa wins FDA nod - BioWorld Online
Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Cyclo-oxygenase 2 Inhibitors Clinical Trial Pipeline - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COFS, ARC, NBY, RFL on Behalf of Shareholders - GlobeNewswire
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm - The Malaysian Reserve
Cyclo Therapeutics Inc Stock (CYTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):